这一数据不仅印证了mRNA肿瘤疫苗能够提供持久免疫应答的科学假设，也为个体化肿瘤疫苗的市场前景提供了有力佐证，同时进一步增强了资本市场对个性化癌症治疗赛道成长性的关注。受消息影响，莫德纳当天股价上涨2.8%，随着mRNA产品临床推进，其股价重拾升势，最新价已逼近近一年高点。据悉，莫德纳已将该疫苗列为预计2027年上线的主要增长驱动力之一。

Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Lipid nanoparticles, such as the one shown in this illustration, are used as vehicles to deliver mRNA-based vaccines. The U.S. Department of Health and Human Services announced on Tuesday that it will ...

If you think last week's decision by the federal government to halt $500 million in funding for vaccine development projects that use mRNA technology will only affect COVID vaccines, think again.

The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.

Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage” of the revenue generated by Spikevax ...

Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine—which designs nanotechnology-based ...

The path to therapeutic cancer vaccines is strewn with disappointment. In the 20-year history of clinical trials for vaccines that are designed to treat existing cancer by stimulating the immune ...

Researchers in Philadelphia reacted with alarm this week when the Department of Health and Human Services announced it is cutting $500 million in funding for mRNA vaccine development. But the cuts ...

COVID vaccine technology could help reduce disabilities in people caused by injuries from snakebites. Researchers at the University of Reading, England, found that the same mRNA tech used in ...